Is IMTXW or STAG a better dividend investment in 2026?

IMTXW currently yields 333333.33% with a 5% 5-year dividend growth rate. STAG yields 3.44% with 1% growth. The better choice depends on your goal: IMTXW offers higher current income.

What is the dividend yield difference between IMTXW and STAG?

IMTXW has a forward dividend yield of 333333.33% ($2.00/share annually). STAG yields 3.44% ($1.24/share annually). The yield gap is 333329.89 percentage points.

Home › Compare › IMTXW vs STAG

IMTXW vs STAG: Dividend Comparison 2026

IMTXW yields 333333.33% · STAG yields 3.44%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 IMTXW wins by $8.099219044190773e+31M in total portfolio value

INVESTMENT

TIME HORIZON10 years

IMTXW

● Live price

333333.33%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$8.099219044190773e+31M

Annual income

$80,944,421,463,343,720,000,000,000,000,000,000,000.00

Full IMTXW calculator →

STAG

STAG Industrial Inc.

● Live price

3.44%

Share price

$36.09

Annual div

$1.24

5Y div CAGR

0.3%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$18.3K

Annual income

$462.22

Full STAG calculator →

Portfolio growth — IMTXW vs STAG

📍 IMTXW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	IMTXW	STAG
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, IMTXW + STAG cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

IMTXW pays

STAG pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IMTXW

Annual income on $10K today (after 15% tax)

$28,333,333.33/yr

After 10yr DRIP, annual income (after tax)

$68,802,758,243,842,160,000,000,000,000,000,000,000.00/yr

STAG

Annual income on $10K today (after 15% tax)

$292.45/yr

After 10yr DRIP, annual income (after tax)

$392.89/yr

At 15% tax rate, IMTXW beats the other by $68,802,758,243,842,160,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IMTXW + STAG for your $10,000?

IMTXW: 50%STAG: 50%

100% STAG50/50100% IMTXW

Portfolio after 10yr

$4.0496095220953863e+31M

Annual income

$40,472,210,731,671,860,000,000,000,000,000,000,000.00/yr

Blended yield

99.94%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on STAG right now

IMTXW

No analyst data

Altman Z

-1.0

Piotroski

3/9

STAG

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$45.00

+24.7% upside vs current

Range: $39.00 — $59.00

Altman Z

1.2

Piotroski

5/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IMTXW buys

STAG buys

No recent congressional trades found for IMTXW or STAG in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricIMTXWSTAG

Forward yield	333333.33% ✓	3.44%
Annual dividend / share	$2.00 ✓	$1.24
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0.3% ✓
Portfolio after 10y	$8.099219044190773e+31M	$18.3K ✓
Annual income after 10y	$80,944,421,463,343,720,000,000,000,000,000,000,000.00 ✓	$462.22
Total dividends collected	$8.098906375781879e+31M ✓	$4.0K
Payment frequency	quarterly	monthly
Sector	Stock	REIT

Year-by-year: IMTXW vs STAG ($10,000, DRIP)

Year	IMTXW Portfolio	IMTXW Income/yr	STAG Portfolio	STAG Income/yr	Gap
1← crossover	$33,344,033	$33,333,333.33	$10,665	$345.09	+$33.33M → IMTXW
2	$103,911,171,366	$103,875,493,250.26	$11,364	$357.70	+$103911.16M → IMTXW
3	$302,644,656,190,810	$302,533,471,237,448.00	$12,098	$370.43	+$302644656.18M → IMTXW
4	$823,817,797,451,856,400	$823,493,967,669,732,100.00	$12,869	$383.28	+$823817797451.84M → IMTXW
5	$2,095,836,995,961,804,000,000	$2,094,955,510,918,530,000,000.00	$13,677	$396.23	+$2095836995961804.00M → IMTXW
6	$4,983,251,920,823,462,000,000,000	$4,981,009,375,237,783,000,000,000.00	$14,524	$409.27	+$4983251920823461888.00M → IMTXW
7	$11,073,835,968,753,321,000,000,000,000	$11,068,503,889,198,040,000,000,000,000.00	$15,411	$422.41	+$1.1073835968753322e+22M → IMTXW
8	$22,999,277,308,531,336,000,000,000,000,000	$22,987,428,304,044,770,000,000,000,000,000.00	$16,339	$435.61	+$2.2999277308531335e+25M → IMTXW
9	$44,643,905,199,991,210,000,000,000,000,000,000	$44,619,295,973,271,085,000,000,000,000,000,000.00	$17,311	$448.89	+$4.464390519999121e+28M → IMTXW
10	$80,992,190,441,907,720,000,000,000,000,000,000,000	$80,944,421,463,343,720,000,000,000,000,000,000,000.00	$18,327	$462.22	+$8.099219044190773e+31M → IMTXW

IMTXW vs STAG: Complete Analysis 2026

IMTXW — Stock

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401, which is in Phase 1b clinical trial; and IMA402 and IMA403, which are in preclinical stages. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Full IMTXW Calculator →

STAG — REIT

STAG Industrial, Inc. (NYSE: STAG) is a real estate investment trust focused on the acquisition and operation of single-tenant, industrial properties throughout the United States. By targeting this type of property, STAG has developed an investment strategy that helps investors find a powerful balance of income plus growth.

Full STAG Calculator →

📬

Get this IMTXW vs STAG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IMTXW vs SCHD IMTXW vs JEPI IMTXW vs O IMTXW vs KO IMTXW vs MAIN IMTXW vs PLD IMTXW vs EQR IMTXW vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.